Subcutaneous Tocilizumab Versus Placebo in Combination With Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis

OBJECTIVE: The efficacy and safety of subcutaneous tocilizumab (TCZ-SC) versus subcutaneous placebo (PBO-SC) was evaluated in patients with rheumatoid arthritis who had an inadequate response to disease-modifying antirheumatic drugs in the BREVACTA study. METHODS: Patients (n = 656) were randomized...

Descripción completa

Detalles Bibliográficos
Autores principales: Kivitz, Alan, Olech, Ewa, Borofsky, Michael, Zazueta, Beatriz M, Navarro-Sarabia, Federico, Radominski, Sebastião C, Merrill, Joan T, Rowell, Lucy, Nasmyth-Miller, Clare, Bao, Min, Wright, Stephen, Pope, Janet E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4276289/
https://www.ncbi.nlm.nih.gov/pubmed/24942540
http://dx.doi.org/10.1002/acr.22384

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4276289/
https://www.ncbi.nlm.nih.gov/pubmed/24942540
http://dx.doi.org/10.1002/acr.22384

Ejemplares similares